Aelis Farma SA (EPA:AELIS)

Market Cap	19.37M -34.2%
Revenue (ttm)	2.33M -78.4%
Net Income	-8.20M
EPS	-0.60
Shares Out	13.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,265
Average Volume	123,532
Open	1.400
Previous Close	1.380
Day's Range	1.390 - 1.490
52-Week Range	0.672 - 2.300
Beta	0.66
RSI	52.33
Earnings Date	Mar 30, 2026

About Aelis Farma

Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase II clinical trials to treat cognitive deficits observed in down syndrome, as well as other cognitive imp...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 24
• Stock Exchange: Euronext Paris
• Ticker Symbol: AELIS

Financial Performance

In 2024, Aelis Farma's revenue was 5.56 million, a decrease of -54.99% compared to the previous year's 12.36 million. Losses were -7.46 million, 46.8% more than in 2023.